ArticleGastrointestinal stromal tumor2021
A narrative review of imatinib-resistant gastrointestinal stromal tumors.
Article in Gastrointestinal stromal tumor, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06507683 (A Multicenter, Single-arm, Prospective Study to Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Single-arm, Prospective Study to Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST
Who cites it
9 citing papers in PubMed, 5 citations in OpenAlex.
- Oligometastatic GIST: Impact of Treatment Modalities and Metastatic Distribution on Overall Survival.Cancers · 2026Article
- Paeoniflorin's role in inhibiting malignant metastasis of gastrointestinal stromal tumors via CYP3A4 modulation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Interpreting ctDNA dynamics in gastrointestinal stromal tumor (GIST) therapy-timing may be key.Journal of gastrointestinal oncology · 2026Article
- Prognostic inflammatory-immune score-based risk stratification optimizes adjuvant therapy for non-gastric gastrointestinal stromal tumors: a multicenter study.Frontiers in immunology · 2026Article
- Surgical treatment of gastrointestinal stromal tumors.Journal of medicine and life · 2026Review
- Primary extra-gastrointestinal stromal tumor of the gallbladder: A case report.World journal of gastroenterology · 2025Article
- Cellular Senescence, Inflammation, and Cancer in the Gastrointestinal Tract.International journal of molecular sciences · 2023Review
- Clinicopathological, immunohistochemical, molecular-genetic and risk profiles of gastrointestinal stromal tumors in a cohort of Sudanese patients.African health sciences · 2023Article
- Aging of enteric neuromuscular systems in gastrointestinal tract.Neurogastroenterology and motility · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Objective: Review the studies that investigate the mechanisms underlying imatinib-resistant gastrointestinal stromal tumors (GIST). Background: GIST are the most common mesenchymal tumors of the gastrointestinal (GI) tract and the most common sarcoma in humans. GIST are thought to be arise from interstitial cells of Cajal (ICC), pacemaker and neuromodulator cells in the GI tract, as well as "fibroblast"-like cells, which are another type of interstitial cells of the gut wall and also known as telocyte or platelet-derived growth factor-alpha (PDGFRA)-positive cells. The majority of GIST harbor gain-of-function mutations in either Methods: We review our current optimal treatment approach for managing patients with advanced and refractory GIST. Conclusions: This review explores the novel and potential therapeutic approaches to combat drug-resistant GIST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.